Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Priority Review for Genentech’s Inavolisib in PIK3CA-mutated Breast Cancer
Details : GDC-0077 (inavolisib) is a PI3K alpha Inhibitor in combination with palbociclib and fulvestran, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer.
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 29, 2024
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Inavolisib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Breakthrough Therapy Designation to Inavolisib for Advanced Breast Cancer
Details : GDC-0077 (inavolisib) is an oral therapy for PI3Kα inhibition. It is in phase 3 trials for treatment of advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 21, 2024
Lead Product(s) : Inavolisib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GDC-0077 (inavolisib) is an investigational, highly selective inhibitor and degrader of mutant PI3K alpha. It is being evaluated in combination with palbociclib & fulvestrant for the treatment of HER2-negative breast cancer With a PIK3CA Mutation.
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2023
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GDC-0077 (inavolisib) is an oral therapy with high in vitro potency and selectivity for PI3Kα inhibition. It is being evaluated in phase 3 trials for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3C...
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GDC-0077 (inavolisib palbociclib fulvestrant) is a PI3K alpha Inhibitor Small molecule drug candidate, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer with a PIK3CA mutation via oral tablet.
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?